New data presented at conference show satralizumab (Enspryng) reduces risk and severity of relapse in neuromyelitis optica spectrum disorder (NMOSD)

In pooled analysis of the SAkura studies (SAkuraSky, SAkuraStar), this anti-IL-6 receptor monoclonal antibody reduced the risk of relapse in combined double-blind period and open-label extension by 51% (HR, 0.49; 95% CI, 0.31–0.79) vs. those originally in placebo group.


Biospace Inc.